Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dhananjaya Pal

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Life Sciences|March 17, 2016
A novel bisindole-PBD conjugate inhibits angiogenesis by regulating STAT3 and VEGF in breast cancer cellsPranjal Sarma, M Janaki Ramaiah, Dhananjaya Pal, et al.
Drug Discovery Today|January 27, 2024
Recent advances in multitarget-directed ligands via in silico drug discoveryKrishnaiah Maddeboina, Bharath Yada, Shikha Kumari, et al.
Plos One|July 29, 2016
Regulation of Cell Proliferation and Migration by miR-203 via GAS41/miR-10b Axis in Human Glioblastoma CellsDhananjaya Pal, Debasmita Mukhopadhyay, M Janaki Ramaiah, et al.
Scientific Reports|July 23, 2020
Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targetsKendra R Vann, Dhananjaya Pal, Guillermo A Morales, et al.
Biomedical Chromatography : BMC|April 12, 2023
LC-MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studiesVeenu Bala, Yashpal S Chhonker, Guillermo A Morales, et al.
Molecular Biomedicine|January 15, 2022
Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphomaKendra R Vann, Dhananjaya Pal, Audrey L Smith, et al.
Iscience|September 24, 2021
The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphomaDhananjaya Pal, Kendra R Vann, Shweta Joshi, et al.
Antiviral Research|May 10, 2024
SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2Kabita Pandey, Arpan Acharya, Dhananjaya Pal, et al.
European Journal of Medicinal Chemistry|May 21, 2026
Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitorsKrishnaiah Maddeboina, Bharath Yada, Cody C McHale, et al.
Plos One|March 30, 2021
Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interactionMona Al-Mugotir, Jeffrey J Lovelace, Joseph George, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Life Sciences|March 17, 2016
A novel bisindole-PBD conjugate inhibits angiogenesis by regulating STAT3 and VEGF in breast cancer cellsPranjal Sarma, M Janaki Ramaiah, Dhananjaya Pal, et al.
Drug Discovery Today|January 27, 2024
Recent advances in multitarget-directed ligands via in silico drug discoveryKrishnaiah Maddeboina, Bharath Yada, Shikha Kumari, et al.
Plos One|July 29, 2016
Regulation of Cell Proliferation and Migration by miR-203 via GAS41/miR-10b Axis in Human Glioblastoma CellsDhananjaya Pal, Debasmita Mukhopadhyay, M Janaki Ramaiah, et al.
Scientific Reports|July 23, 2020
Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targetsKendra R Vann, Dhananjaya Pal, Guillermo A Morales, et al.
Biomedical Chromatography : BMC|April 12, 2023
LC-MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studiesVeenu Bala, Yashpal S Chhonker, Guillermo A Morales, et al.
Molecular Biomedicine|January 15, 2022
Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphomaKendra R Vann, Dhananjaya Pal, Audrey L Smith, et al.
Iscience|September 24, 2021
The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphomaDhananjaya Pal, Kendra R Vann, Shweta Joshi, et al.
Antiviral Research|May 10, 2024
SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2Kabita Pandey, Arpan Acharya, Dhananjaya Pal, et al.
European Journal of Medicinal Chemistry|May 21, 2026
Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitorsKrishnaiah Maddeboina, Bharath Yada, Cody C McHale, et al.
Plos One|March 30, 2021
Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interactionMona Al-Mugotir, Jeffrey J Lovelace, Joseph George, et al.
Pageof 2